Senator Dick Durbin, D-Illinois, a co-sponsor of the amendment, placed blame on pharmaceutical companies for using their influence to block the measure.
US lawmakers have been in a hurry this week to deliver the first set of 2019 appropriations bills to the President for approval. In an effort to deliver on a piece of the administration’s drug pricing blueprint, a bipartisan provision that would have required drug manufacturers to include list prices in direct-to-consumer television ads was expected to be included in the bill. The provision was subsequently blocked by House Republicans.
Senator Dick Durbin, D-Illinois, a co-sponsor of the amendment, placed blame on pharmaceutical companies for using their influence to block the measure. “For some reason, someone on the other side is trying to block this common sense, truly bipartisan policy. When are we going to stand up to Big Pharma and actually do something about sky high prescription drug prices? Transparency in advertising is the very least Congress can do,” said Durbin, as reported in Regulatory Focus.
Senator Chuck Grassley, R-Iowa, the other co-sponsor of the amendment, took to Twitter to announce his disappointment with the amendment’s exclusion, stating “It is EMBARRASSING to bow to BIG PHARMA at expense of consumers... If we can agree why are lobbyists fighting?”
Industry did indeed take issue with the amendment; the Pharmaceutical Research and Manufacturers of America(PhRMA) spoke out against the proposal in its July comments to HHS on the administration’s drug pricing blueprint, saying “FDA should not pursue any required disclose of list prices in direct-to-consumer pharmaceutical advertising. Such a requirement could confuse patients since the list price often does not represent what they would actually be required to pay.”
Exclusion of the amendment appears to counter public sentiment; a recent poll from the Kaiser Family Foundation found that nearly 76% of the public supports the inclusion of list prices in television ads.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.